biotx

biotx.ai is a Munich-based, privately-held AI/ML biotech founded in 2018. The company has developed a proprietary causal inference platform that applies Mendelian randomization at an unprecedented scale, analyzing billions of data points from genome-wide association studies (GWAS) to establish high-confidence causal relationships between genes, biomarkers, and diseases. This platform is designed to de-risk drug discovery by providing genetic validation for targets and predicting clinical efficacy, addressing the high failure rates in Phase 2 trials. biotx.ai operates as a platform technology company, likely engaging in partnerships with pharmaceutical firms to leverage its causal maps and AI models.

A proprietary causal inference platform that applies large-scale Mendelian randomization and colocalization across thousands of GWAS datasets to generate billions of causal links between genes, omics markers, and diseases. AI models are trained on this causally annotated data to map human biology and identify/validate drug targets.

biotx.ai competes in the broad AI/ML drug discovery space against companies like Exscientia, Recursion, and Insilico Medicine. Its specific focus on causal inference via Mendelian randomization differentiates it from many competitors who rely more on associative machine learning. It may also face competition from large genetics data providers (e.g., UK Biobank-based researchers) and specialized causal inference startups.